← Back to Search

18F-PSMA PET + MRI for Prostate Cancer

Phase 2

Waitlist Available

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult patient (≥ 18 years old) with a diagnosis of at least Gleason Grade Group 2 prostate cancer

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, this is expected to be reviewed within 1 year of imaging

Awards & highlights

Study Summary

This trial is testing how accurate second-generation prostate-specific membrane antigen PET scans are at locating clinically significant prostate cancer in men who are also undergoing MRI scans.

Who is the study for?

This trial is for adult men diagnosed with at least Gleason Grade Group 2 prostate cancer who've had initial staging scans. They must be able to give consent, lie flat for imaging, and have kidneys working well enough (eGFR ≥ 40). It's not for those over 250 kg, with non-MRI safe implants, severe MRI dye reactions or claustrophobia.Check my eligibility

What is being tested?

The study compares the accuracy of a new PET scan using a tracer called 18F-PSMA-1007 and standard MRI in determining the extent of prostate cancer before surgery. Each participant will undergo both tests to see how they stack up against traditional CT and bone scans.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to contrast materials used in MRI or PET scans, discomfort from lying still during imaging procedures, and exposure to radiation from the PET scan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an adult with prostate cancer at or above Gleason Grade 2.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, this is expected to be reviewed within 1 year of imaging

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, this is expected to be reviewed within 1 year of imaging

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, this is expected to be reviewed within 1 year of imaging for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Tumor T-staging

Secondary outcome measures

Identification of dominant lesion

Identification of non-dominant lesion

Longest Tumor diameter

+10 more

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Canadian Urological Association Scholarship FoundationUNKNOWN

University of AlbertaLead Sponsor

889 Previous Clinical Trials

384,988 Total Patients Enrolled

9 Trials studying Prostate Cancer

5,404 Patients Enrolled for Prostate Cancer

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT05141760 — Phase 2

Prostate Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT05141760 — Phase 2

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT05141760 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are you looking for more people to participate in this experiment?

"Yes, the data on clinicaltrials.gov says that this trial is actively looking for candidates. The study was originally posted on 2/10/2022 and was last edited on 5/10/2022. The study is looking for 150 patients across 1 site."

Answered by AI

How many total participants are being allowed in this experiment?

"Indeed, the information available on clinicaltrials.gov makes it clear that this trial is still recruiting patients. The listing was first posted on February 10th, 2022 and updated May 10th, 2022. They are looking for a total of 150 individuals across 1 site."

Answered by AI